Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.

Triapine, a potent inhibitor of ribonucleotide reductase, has demonstrated anti-leukemia activity in pre-clinical models. We conducted a Phase I study of Triapine administered as a 2 h infusion for 5 days in 25 adults with advanced leukemias. We established that Triapine at 96 mg/m2 once a day can be given safely on days 1-5 and 15-19 or 1-5 and 8-12 of a 4-week cycle. When administered twice a day on days 1-5 and 8-12, the maximum tolerated dose of Triapine appears to be 64 mg/m2, although the true criteria for DLT were not met by protocol definition. No CR or PR were observed, but 76% of patients had a >50% reduction in white blood cell counts. At all dose levels, the peak plasma concentration of Triapine (2.2-5.5 microM) was above levels required to achieve in vitro/in vivo leukemia growth inhibition. Based on these data, we conclude that Triapine warrants further investigation in hematologic malignancies.
AuthorsIvana Gojo, Michael L Tidwell, Jacqueline Greer, Naoko Takebe, Karen Seiter, Mary F Pochron, Bonny Johnson, Mario Sznol, Judith E Karp
JournalLeukemia research (Leuk Res) Vol. 31 Issue 9 Pg. 1165-73 (Sep 2007) ISSN: 0145-2126 [Print] England
PMID17324462 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • Pyridines
  • Thiosemicarbazones
  • 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
  • Ribonucleotide Reductases
  • Adult
  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (administration & dosage, pharmacokinetics)
  • Female
  • Humans
  • Infusions, Intravenous
  • Leukemia (blood, drug therapy)
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Pyridines (administration & dosage, pharmacokinetics)
  • Ribonucleotide Reductases (antagonists & inhibitors)
  • Thiosemicarbazones (administration & dosage, pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: